Family · Pharmaceutical analytical standards
Ezetimibe
It lowers cholesterol by blocking its absorption in the gut, and was approved in 2002. It is often combined with a statin, which instead blocks cholesterol production in the liver. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It was found while searching for a medicine with a different mechanism: its real target, the NPC1L1 protein, was only identified in 2004, two years after approval.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
